Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

(2015) Priska Kaufmann et al.   American Journal of Cardiovascular Drugs

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

(2015) Priska Kaufmann et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study

(2015) Daniela Baldoni et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Selexipag for the Treatment of Pulmonary Arterial Hypertension

(2015) Olivier Sitbon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects

(2014) Shirin Bruderer et al.   PHARMACOLOGY

Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

(2012) Gérald Simonneau et al.   EUROPEAN RESPIRATORY JOURNAL

Selexipag: A Selective Prostacyclin Receptor Agonist that Does Not Affect Rat Gastric Function

(2010) K. Morrison et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS